What Merxin does

Merxin Ltd is a UK-based designer and supplier of generic and customized inhaler device platforms, founded in 2015 and headquartered in King's Lynn, Norfolk. The company serves pharmaceutical companies and generic drug developers globally, providing device platforms that customers combine with their own drug formulations to create finished inhaled dosage forms for conditions including asthma, COPD, IPAH, cystic fibrosis, and pulmonary hypertension. Merxin operates as a B2B enterprise supplier across the full lifecycle from evaluation through clinical trials to commercial supply, with a sales-led, contact-based go-to-market motion and customized multi-year contracts.

Merxin's core technology spans the principal OINDP (Orally Inhaled and Nasal Drug Products) device categories. The portfolio comprises four marketed platforms: MRX001 (multidose blister DPI, FDA-approved 2019), MRX002+ (clear PET vial for pMDI formulation screening, compatible with HFA 152a, HFO 1234ze, HFA 227, and HFA 134a propellants), MRX003 (capsule DPI with FDA substitutability and CE marking, used in Glenmark's Tiogiva), and MRX004 (mechanically-driven aqueous soft mist inhaler, no battery or propellant, licensed for US and EU markets). The pipeline is anchored by MRX006, an open-inhale-close multidose DPI with dual cavities for triple combination therapies and chemically incompatible APIs, which completed its first clinical study in 2025. Manufacturing is delivered through global partners including Oechsler (SMI Powerhouse, launched December 2024) and Perlen (BLISTair co-development).

Merxin's business model combines hardware sales of device platforms, licensing royalties (notably MRX004 licensed for US and EU markets in 2022), and regulatory support services. The company is ISO 13485:2016 certified by BSI, qualifying it to supply regulated markets including the EU, Japan, Canada, Australia, and the US. It holds one disclosed external capital event — a December 2018 EU Regional Development Fund grant — and remains a privately held company with no stock exchange listing. Co-founders Graham Purkins (CTO, ex-3M Health Care, Novartis, Bespak) and Philippe Rogueda (CBO, fellow of the Woolcock Respiratory Institute, ex-Actavis) lead the company, with Chris Hall joining as Non-Executive Chairman in December 2024.

Name

Merxin

Legal name

Merxin Ltd

Website

https://merxin.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Merxin Ltd is a UK-based designer and supplier of generic and customized inhaler device platforms, including dry powder and soft mist inhalers, for pharmaceutical companies and generic drug developers worldwide. Founded in 2015 and headquartered in King's Lynn.

Ownership category

akta.pro rank

Product category

Inhaler Medical Devices

NAICS

Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Inhalers (MDI/DPI/SMI) (HLAHAIAI)

akta.pro secondary industries

Inhalation & Nebulization Devices (Nebulizers, Spacers, Inhaler Accessories) (HLAHAGAE), Nebulizers & Aerosol Drug Delivery Systems (HLAHAIAJ)

Keywords

• Inhaler device platforms
• Dry powder inhalers
• Soft mist inhalers
• Generic OINDP devices
• PMDI components

Headquarters

HQ city

King's Lynn

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Device Platform Sales: Sale of generic and customized inhaler device platforms to pharmaceutical companies. Devices are supplied for evaluation, clinical trials, and commercial supply. Customers combine devices with their drug formulations to create finished dosage forms.
2. Licensing Royalties: Licensing of device technologies such as MRX004 licensed for US and EU markets. Royalties from device platforms licensed to pharmaceutical partners.
3. Regulatory Support Services: Supporting customers with documentation, testing, and regulatory compliance for device filing across global markets including EU, US, Japan, Canada, and Australia.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Core offering

Merxin Ltd designs and supplies generic and customised inhaler device platforms for the pharmaceutical industry. Its product range includes the MRX002+ clear PET vial for pMDI formulation studies, the MRX003 capsule dry powder inhaler, the MRX004 soft mist inhaler for liquid and biologic formulations, and the MRX006 multidose dry powder inhaler for triple combination therapies. Pharmaceutical customers combine these devices with their own drug formulations to create finished dosage forms supplied to patients.

Product overview

Merxin Ltd is a designer and supplier of generic and customised inhaler device platforms for the pharmaceutical industry. Their product portfolio consists of four distinct device platforms: MRX002+ (clear PET vial for pMDI formulation screening, laboratory use only), MRX003 (capsule dry powder inhaler for tiotropium DPI with AB-rating), MRX004 (soft mist inhaler for tiotropium/olodaterol with AB-rating), and MRX006 (multidose dry powder inhaler with dual cavities for triple combination therapies). Customers take these devices and combine them with their drug formulations to create final dosage forms. The company supplies platforms from evaluation through to commercial supply.

Differentiator

Problem solved

Functional benefit

Products and services

• MRX003 Capsule Dry Powder Inhaler Generic capsule-based inhaler designed as an AB-rated substitutable device for tiotropium DPI, with dimensions of 65x70x28mm accommodating size 3 capsules, airflow and NGI profile matching the originator Spiriva HandiHaler (tiotropium). Pharmaceutical customers combine it with their drug formulation to create finished tiotropium DPI products such as Glenmark's Tiogiva (launched 2021).
• MRX004 Soft Mist Inhaler Active aqueous soft mist inhaler creating a fine, slow-moving aerosol, mechanically driven with no battery or propellant, with cartridge-based aqueous formulations (108mm x 38mm). Developed as an interchangeable AB-rated generic device for tiotropium/olodaterol and suitable for liquid formulations, new molecules, life cycle management and repurposing from nebulisers or pMDI/DPI, including inhaled GLP-1 and biomolecules.
• MRX006 Multidose Dry Powder Inhaler Open-inhale-close multidose DPI with dual cavities designed for triple combination therapies such as fluticasone, umeclidinium and vilanterol, featuring API segregation, AB-rated substitutable device positioning, and proprietary patent pending technology for triple therapy delivery.
• MRX002+ PET Vial for pMDIs Clear polymer vial for low-carbon-footprint pMDIs, compatible with HFA 152a, HFO 1234ze, HFA 227 and HFA 134a propellants, designed for laboratory formulation screening and in-situ observation of pMDI formulations. Intended for laboratory use only, not for clinical use.
• Regulatory and Filing Support Services Support services bundled with device platform supply, including documentation, testing and regulatory compliance assistance for device filing across global markets such as EU, US, Japan, Canada and Australia, underpinning clients' finished dosage form approvals.
• Cannabinoid Delivery Inhaler Devices Specialised inhaler devices from Merxin's portfolio tailored to deliver cannabinoid formulations to the lungs, addressing the cannabinoid therapy market as a differentiated OINDP application.

Quantifiable outcome

• MRX003 received FDA substitutability approval as suitable generic device for Spiriva HandiHaler (tiotropium) 505j ANDA filing
• +3 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Five partnerships are on record, tiered core and supporting.

• CorriXR TherapeuticscoreStrategic or Co-development Partner · 3 December 2025Strategic collaboration for the development of inhaled lung cancer treatment. Merxin providing device expertise and technology platform for pulmonary delivery of lung cancer therapeutics.
• InhaTarget Therapeutics LtdcoreStrategic or Co-development Partner · 3 December 2025Strategic collaboration for the development of inhaled lung cancer treatment. Combined expertise in inhalation technology and targeted therapeutic delivery for lung cancer.
• OechslercoreStrategic or Co-development Partner · 1 December 2024Strategic partnership to launch The SMI Powerhouse - manufacturing partnership for soft mist inhaler production. Combined Oechsler's manufacturing expertise with Merxin's SMI technology platform for scalable production of MRX004 soft mist inhalers.
• PerlencoreStrategic or Co-development PartnerPartnership to develop BLISTair - collaborative development of inhalation device technology combining Perlen's capabilities with Merxin's device expertise.
• Royal SocietysupportingOthersAppointment of Professor Darragh Murnane as Royal Society Short Industry Fellow - research collaboration bringing academic expertise to support Merxin's device development capabilities.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• West Pharmaceutical Services: Major pharmaceutical containment and drug delivery device company with elastomer components and device platforms including inhalation delivery systems. Larger, broader incumbent with overlapping inhaler technology serving pharma customers globally.
• AptarGroup (Aptar Pharma): Global leader in drug delivery devices including metered-dose inhalers, dry powder inhalers, and nasal spray platforms for pharmaceutical companies. Aptar Pharma is a broad incumbent in the OINDP device space and the most direct large-scale competitor to Merxin's inhaler platforms.
• Becton Dickinson (BD Medical): Global medical device and pharmaceutical systems manufacturer offering drug delivery devices including prefilled syringes and injectors. A broader medical device incumbent with strategic interest in advanced drug delivery — overlaps with Merxin in pharmaceutical device supply and regulatory support.
• Vectura (Philip Morris International): Established inhalation drug delivery company (now part of Philip Morris) specializing in DPI technology and licensing. Acquired by Philip Morris in 2024, Vectura was historically one of the most comparable generic and innovator inhaler platform licensors to Merxin in DPI development.

Direct peers

• Hovione: Portuguese pharmaceutical contract manufacturer and device developer with strong inhalation expertise, offering inhaler device development, formulation services, and commercial supply to pharma customers. Competes directly with Merxin in OINDP drug-device combination development.
• Sanner Group: German manufacturer of plastic packaging and drug delivery devices including inhaler components and DPI desiccant solutions for pharmaceutical companies. Direct peer in supplying inhaler device components and integrated devices to pharma developers.
• Kindeva Drug Delivery: CDMO specializing in complex drug-device combination products including inhalation and nasal drug delivery solutions, formed from the merger of 3M's Drug Delivery Systems business. Directly comparable to Merxin as a focused inhalation device platform provider serving pharma customers.
• SkyePharma (subsidiary of Vectura/Philip Morris): Drug delivery company specializing in oral and pulmonary pharmaceutical technologies including DPI and pMDI development. Provides inhaled drug delivery platform services comparable to Merxin's end-to-end device platform model.
• Nemera: Drug delivery device manufacturer with a portfolio of inhalation, nasal, ophthalmic, and injectable device platforms including DPI and pMDI technology. Direct peer to Merxin in providing inhaler and respiratory drug delivery platforms to pharmaceutical developers.

Emerging players

• Coalesce Product Development: Boutique consultancy offering inhaled drug delivery device development expertise to pharmaceutical companies, with focus on enabling early-stage inhaler programs. Emerging player in the niche of supporting pharma clients with inhaler device design and development, comparable in capability scope to Merxin's platform offering.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/mrxdevices
• LinkedInlinkedin.com/company/merxin-ltd

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Merxin